46 Search Results


Search Again

Geoffrey Baird , MD, PhD

Email: gbaird@uw.edu

Phone: (206)744-9787

Dr. Baird's clinical interests include laboratory test utilization, molecular diagnostics, proteomics and immunohistochemistry. His group has developed a new proteomic technology for biomarker discovery in a range of diseases such as malignancies, cardiovascular disorders, and inflammatory conditions. One application of their technology is to discover protein expression changes associated with non-small cell lung cancer that have implications for diagnosis and treatment.

View Bio

Parveen Bhatti , PhD

Email: pbhatti@fredhutch.org

Phone: (206) 667-7803

Dr. Bhatti's research focus is on occupational and environmental epidemiology of cancer with a focus in biomarkers of exposure, susceptibility and disease; particularly genetic susceptibility to cancer following low dose exposure to occupational or medical ionizing radiation.

View Bio

Roger Brent , PhD

Email: rbrent@fredhutch.org

Phone: (206) 667-1482

Dr. Brent studies the quantitative operation of the systems that living cells use to sense, represent, transmit, and act upon information to make decisions that determine their future fates. He specifically studies prototypic cell signaling systems in budding yeast and the pheromone response system; he has extended similar work to systems operating in single cells of tissues in a metazoan, Caenorhabditis elegans.

View Bio

James (Jim) Brinkley , MD, PhD

Email: brinkley@u.washington.edu

Phone: (206) 543-3954

Dr. Brinkley's primary research interest is biomedical informatics - the representation, management, sharing, visualization and utilization of neuroscience data and knowledge. He is the founder of the field of Structural Informatics, which has as its goal the development of methods for representing the structure of the body at multiple levels of detail, as for using these methods for organizing and integrating biomedical information. His aim is to find ways to represent the structure or the body in computer-readable form, and find ways to associate these representations with the myriad biomedical data that are available. His goal is to provide a structural information framework for integrating a huge variety of big and small biomedical data. Dr. Brinkley's projects have included anatomy education, brain mapping through the national Human Brain Project, cardiovascular data integration, clinical trials data integration through the national Clinical translational Science Awards, radiological image annotation and integration through the RadLex project, and craniofacial malformations data integration through the national FaceBase consortium. He is also interested in developing web-accessible computer applications utilizing these representations to solve practical problems in clinical medicine, research and education.

View Bio

Heather Cheng , MD, PhD

Email: hhcheng@u.washington.edu

Phone: (206) 650-2205

Dr. Cheng cares for patients with prostate, bladder, and testicular cancers. Dr. Cheng's research interests include studying new treatments for prostate and bladder cancer through clinical trials, and understanding how to sequence the new drugs to maximize therapeutic benefit for patients. She is also studying blood-based cancer biomarkers, such as microRNAs.

View Bio

James Dai , PhD

Email: jdai@fredhutch.org

Phone: (206) 667-6364

James Dai’s Lab works in statistical genetics and genomics, design and analysis of randomized clinical trials, statistical methods for high-dimensional feature selection and prediction, gene-treatment interaction, mediation and instrumental variables regression. Methodologically, his lab is also interested in cancer genomics topics, for example integrative genomic analyses and intra-tumor heterogeneity. The overarching scientific interest is to discover and validate and genomic markers that drive cancer etiology, predict cancer prognosis and treatment efficacy.

View Bio

Manjiri Dighe , MD, FSAR, FSRU

Email: dighe@uw.edu

Phone: 206-598-0024

Dr. Dighe is section chief of body imaging at the University of Washington and a UW associate professor of radiology. In addition to body imaging, she is an expert in obstetric and thyroid imaging. She also conducts research on thyroid nodules using non-invasive ways to diagnose malignancy which includes ultrasound elastography. She also has a long interest and expertise in obstetric imaging and works closely with the Maternal Fetal Medicine group in UW to diagnose complex cases.

View Bio

Petros Grivas , MD, PhD

Email: pgrivas@uw.edu

Dr. Petros Grivas is a medical oncologist at Seattle Cancer Care Alliance with expertise in genitourinary cancers such as bladder cancer, prostate cancer and testis cancer.

View Bio

Barry Gumbiner , PhD

Email: gumbiner@uw.edu

Phone: 206-884-5116

Dr. Gumbiner and his team study how cadherin cell adhesion molecules and associated catenin proteins control tumor development and progression. Cadherins and catenins play important roles in the morphogenesis, maintenance, and regeneration of tissues, and alterations in their functions are important in cancer. One major effort of the laboratory is to understand how cadherins signal into the cell to control growth and differentiation through regulation of both the Wnt-beta-catenin pathway and the Hippo signaling pathway; the latter inhibits cell proliferation and participates in organ size control. Cadherins mediate contact inhibition of growth by stimulating the Hippo pathway, while growth factors, such as EGF, inhibit the Hippo pathway. They are investigating how these modes of regulation of the Hippo pathway affect the development of different types of tumors. Another major effort of the laboratory is to understand how cadherin adhesive function at the cell surface is regulated to control tissue architecture and tumor cell invasion. Loss of E-cadherin expression associated with the epithelial-mesenchymal transition (EMT) is known to promote tumorigenesis and metastasis. However, many tumors and metastases retain E-cadherin expression, and they have found that instead it can be inactivated at the cell surface to cause the loss in function. They have generated a novel class of monoclonal antibodies that activate E-cadherin at the cell surface to restore its adhesive function, and are evaluating whether they reduce tumor invasion and metastasis in animal models. He and his team are also studying how catenins and cancer-associated mutations in E-cadherin affect its ability to switch to the active state and regulate tumor development. The mechanisms by which cadherins and catenins affect tumor growth are varied and complex and offer potential approaches for intervention.

View Bio

Michael Haffner , MD, PhD

Email: mhaffner@fredhutch.org

Dr. Haffner’s lab focuses on elucidating alterations of the cytoskeleton in solid tumors with a focus on prostate cancer. For instance, they have recently described a novel protein, named AIM1 that regulates cytoskeletal organization by binding to actin, a major component of the cytoskeleton. When AIM1 is present, the cells' scaffolding keeps it rigid and correct shape. When AIM1 is lost, cells can remodel their cytoskeleton more frequently, change their shape and become capable of invading and migrating to distant locations. Notably, AIM1 function is disrupted in many solid tumors and genomic alterations of AIM1 are associated with aggressive tumor growth. The goal of these studies is to understand the mechanisms that govern changes in cell architecture to explore such cancer specific changes for therapeutic targeting.

View Bio

Noah Hoffman , MD, PhD

Email: ngh2@uw.edu

Phone: (206) 598-7932

Dr. Hoffman's clinical interests and responsibilities include the development and application of software and processes for the collection, management, and display of data generated in the clinical laboratory. His research is focused on creating applications and algorithms to classify medically important microorganisms using biological sequence information.

View Bio

Linda Ko , PhD, MPH

Email: lko@fhcrc.org

Phone: (206) 667-7182

Dr. Ko is the director of the Center for Health Communication Intervention (CHEALCI). She is a behavioral scientist with expertise in the development, testing, and evaluation of health communication strategies. Her work draws from the discipline of communication, marketing, social epidemiology, and social and behavioral sciences. Her research aims to understand community behavior within the socio-cultural context, develop interventions that will address those behaviors and translate knowledge through community-based participatory research.

View Bio

Hung-Ming Lam , PhD

Email: minglam@uw.edu

Phone: (206) 543-1461

Dr. Lam is primarily interested in estrogen receptor, prostate cancer and prostate cancer dormancy.

View Bio

Jean Lee , MD

Email: jeanhlee@u.washington.edu

Phone: (206) 598-0023

Dr. Lee is a radiologist who specializes in imaging for high-risk localized prostate cancer. Her clinical expertise is in prostate imaging, hepatobiliary, pancreatic and transplant imaging.

View Bio

Jay Liao , MD

Email: jayliao@uw.edu

Phone: (206) 598-4100

Dr. Liao treats patients with head and neck cancers, salivary gland cancers, skin cancers, genitourinary cancers, and prostate cancer. He specializes in the treatment of head and neck cancers with a number of radiation therapy techniques including IMRT, electron therapy, and fast neutron therapy.

View Bio

Daniel Lin , MD

Email: dlin@u.washington.edu

Phone: (206) 667-1342

Dr. Lin is a urologist specializing in genitourinary oncologic surgery. He clinical expertise is in genitourinary oncology, early detection and prevention, and basic research, including the molecular mechanisms of prostate carcinogenesis.

View Bio

Alvin Liu , PhD

Email: aliu@u.washington.edu

Phone: (206) 221-0603

Dr. Liu is interested in urologic tissue repair and renewal involving intercellular signaling and cell-cell interaction. His lab work concerns cancer cell biology - the involvement of cell-cell interaction through signaling molecules and cell contact in the development of tumor and gene expression changes in tumor cell types.

View Bio